Proactive Investors - Run By Investors For Investors

Breakfast News - AIM Breakfast : Blur Group PLC, Collagen Solutions PLC, Future plc, Netscientific PLC, Proactis Holdings Plc, Thor Mining PLC, UK Oil & Gas Investments PLC

Breakfast News - AIM Breakfast : Blur Group PLC, Collagen Solutions PLC, Future plc, Netscientific PLC, Proactis Holdings Plc, Thor Mining PLC, UK Oil & Gas Investments PLC

What’s cooking in the IPO kitchen?


Altus Strategies—African focused natural resource Company. Offer TBC. Expected Mid July.

Harvey Nash Group— Provider of professional recruitment and offshore solutions moving to AIM from Main. No capital to be raised.  Mkt Cap c. £57.8m.

AnimalCare—RTO of Ecuphar NV, a European animal health company. £30m raise. Ecuphar FY16 rev £68.4m, underlying EBITDA £8.9m. Due 13 July.

Angling Direct  -Schedule 1  from the specialist fishing tackle retailer in the UK . Raising £9m of which £7.4m new money. Mkt cap c. £27.4m.  Due 13 July

NEXUS Infrastructure—£35m vendor sale. Mkt cap £70.5m. Provider of essential infrastructure services to the UK housebuilding and commercial sectors. Expected 11 July. FYSep16 rev £135.7m.

Greencoat Renewables  - Schedule 1. Targeting a portfolio of operating renewable electricity generation assets, initially investing in wind generation assets in Ireland.  Offer TBC. Due Mid July.

QUIZ— Omni-channel fast fashion womenswear Company intention to float. Due July 2017.  Offer TBA

I3 Energy –Schedule 1 Update. Independent oil and gas company with assets and operations in the UK.  Offer TBC, Mid July admission.

Verditek— Sch 1 update. The Company's subsidiaries will be involved in advanced solar photovoltaic, filtration and absorption technologies specialising in providing environmental services. Issue price 10p.  Admission late June

Main Market Standard Listing

Rockpool Acquisitions—Northern Ireland based Company seeking  strong NI acquisition with an international outlook. Raising £1.5m at 10p. Due 5 July.

Main Market Premium Listing

Hipgnosis Songs Fund investment company offering pure-play exposure to Songs and associated musical intellectual property rights. Prospectus yet to be published.

Impact Investment Trust—Exposure to a diversified portfolio of funds providing SMEs across developing economies with the growth capital they need to have a positive impact on the lives of the world's poorer populations. Raising up to $150m at $1.00

Residential Secure  Income -  social housing REIT  raising up to £300m Admission due c.12 July.

Curzon Energy—Report on Proactive Investors of intended LSE float this year  with acquisition of  coal bed methane assets in Oregon. Looking to raise £3m plus.

NLB Group—financial and banking institution based in Slovenia, with a network of 356 branches. Seeking Ljubliana Stock Exchange listing with GDRs on the LSE. Expected mid June.

Kuwait Energy— has not been able to complete its initial public offering as announced in its Intention To Float of 3 May 2017. However, in light of positive feedback from potential investors, the Company remains committed to obtaining a London listing and continues to explore its options.

Main Market Specialist Funds

Supermarket Income REIT– Up to £200m raise to acquire a diversified portfolio of supermarket real estate assets in the UK, providing long-term RPI-linked income. Due 21 July.

Breakfast buffet

Future (LON:FUTR) 265p £96.9m

The global platform for specialist media,  announced the proposed acquisition of the Home Interest division of Centaur Media (CAU.L), a portfolio of market leading and differentiated brands in the home building segment, for cash, at an enterprise value of £32.0m. Raising £22m at 250p. The sale of the Home Interest division by Centaur Media plc is conditional upon the approval of its shareholders. The Acquisition and Placing are interconditional. ‘ Further diversifies Future's revenue streams, adding significant scale in events - a business with good revenue visibility and attractive working capital dynamics’

Trading for the full year is expected to be in-line with the Board's expectations. FYSep17E rev £76.5m, PBT £6.77m.

UK Oil & Gas (LON:UKOG) 3.22p £110.4m

UKOG announced that the Environment Agency has formally granted the necessary permit to flow test the Broadford Bridge-1 ("BB-1") oil exploration well.

The BB-1 well is located in the 300 km(2) PEDL234 licence, in which the Company has a 100% interest via its ownership of the licence's operator, Kimmeridge Oil & Gas Limited.

Stephen Sanderson, UKOG's Executive Chairman, Commented:

"This enables us to move onto the next phase of operation at Broadford Bridge. Our drilling and comprehensive coring programme has been very successful and we look forward to equally positive results from our flow testing operation."

THOR Mining (LON:THR) 1.05p £3.92m

Strategic Outlook Update: H1 highlights include:  Pilot Mountain tungsten drilling - a successful drilling program completed in early March delivered a 55% increase in the resources;   Dundas gold drilling - drilling program has been completed, with assays due shortly;  Spring Hill gold sale completion - A$1.5million received in February, significantly strengthening the Company's balance sheet, and a royalty stream is expected from the Spring Hill project in the medium term. New Projects - June announcement of entry in a Lithium exploration company with projects in Arizona and New Mexico, USA. Calendar H2 is expected to be equally eventful with an exciting new drill program scheduled for Pilot Mountain, and the potential acquisition of the residual 75%  of US Lithium. 

NetScientific (LON:NSCI) 48.5p £33.48m

The transatlantic healthcare IP commercialisation Group, announced that a European patent exclusively licensed to one of its portfolio companies, Glycotest, has been granted. In addition, United States and Australian patents have been allowed. These patents will significantly extend protection for Glycotest's core technology for early detection of life threatening liver disease. As announced on 26 June 2017, the Company is aiming to close a Series A round within the second half of 2017.

Collagen (LON:COS) 5p £16.2m

The developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces the commencement of patient enrolment into an open label extension study as part of the clinical development programme for ChondroMimetic®, an osteochondral scaffold for the repair of cartilage defects in the knee. CE-marking was previously achieved prior to the Company's acquisition of the product and related IP, and this follow-up clinical study is a step towards re-establishing that CE-mark certification.  Targets study completion before year end. FY Mar17E rev £3.95m and £1.8m loss.

DX Group (LON:DX) 9.5p £19.05m

Further to DX's announcement on 9 June, the Board of DX announces that it has been notified by the City of London Police Economic Crime Directorate ("City of London Police") that, after careful consideration of allegations made, the City of London Police will not be proceeding to a full investigation.

The Company co-operated with the City of London Police's preliminary investigation, which centred on the DX Exchange operations, and in addition has reviewed and made changes to internal business processes in this unit, which will be kept under review.  FYJun17E PE c. 12x/ Div 1.25p.

Blur Group (LON:BLUR) 3.13p £1.47m

BLUR (automated Enterprise procurement) intends to raise a minimum of £1.5 million (before expenses) by way of a conditional placing of Ordinary Shares at a price of 1.75 pence per Ordinary Share, a 44% discount to mid. The net proceeds of the Placing are intended to provide blur with sufficient working capital to effect the restructured board's base plan for the business focused on generating new Enterprise customers from the current pipeline during the next 12 months or so. A significant Board reshuffle accompanies the deal.  FY Dec 17E rev £1.4m and £3.18m loss.

PROACTIS Hldgs (LON:PHD) 177.5p £89.17m

The specialist spend management solution provider, has conditionally agreed to acquire all of the outstanding membership interest in Perfect Commerce (PC) a global provider of spend management solutions with operations in the US, UK and Europe, for an aggregate consideration of up to $132.5 million, together with an oversubscribed conditional placing to raise £70.0 million at 165 pence per Placing Share. Expected to be earnings enhancing in first full financial year of ownership. PC 2016 rev $39.7m, $6.4m EBITDA.  FYJul17E rev £25.4m and PBT £5.17m.

MYCELX (LON:MYX) 97.5p £18.17m

H1Jun17 trading update from the clean water technology company providing patented solutions for the Oil and Gas market and commercial industrial markets worldwide. H1 2017 revenues were in line with the Board's expectations. This follows an active first half of the year which, as previously announced, included the first contract award in the Nigerian Oil and Gas market, as well as a contract with a new SABIC affiliate customer.  The Company remains on track to meet current guidance of being operationally cash neutral for the full year.

LightwaveRF (LON:LWRF) 27.25p £10.56m

The smart home solutions provider, is delighted to announce that its next generation Lightwave Link Plus has been certified under Apple's licensing scheme as a "Works with Apple HomeKit" product. The new Lightwave Link Plus connects to a standard WiFi router and controls the integrated LightwaveRF smart home system for lighting, heating, power and security.  This manages Lightwave end-point devices through both Apple Home and LightwaveRF apps and via voice control. The Lightwave Link Plus supports the current Lightwave product range as well the new range of devices to be launched later this year.

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use